Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04861051 · ClinicalTrials.gov registry record · Phase 1
Understanding Ketamine's Dissociative Effects (KD Study)
A Phase 1 study of Epilepsy, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04861051 is a Phase 1 study of Epilepsy that is actively recruiting participants, run by Stanford University. The registered enrollment target is 20 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04861051, a Phase 1 study of Epilepsy, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand how ketamine brings about dissociative symptoms.
Conditions Studied
Interventions
- DRUG Ketamine
Study Locations (1)
California
- Stanford University School of Medicine - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-07-26 |
| Est. Completion | 2028-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04861051
The ClinicalTrials.gov registry entry for NCT04861051 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (98% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Ketamine is the first listed.
NCT04861051 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04861051 about?
NCT04861051 is a clinical study titled "Understanding Ketamine's Dissociative Effects (KD Study)". The purpose of this study is to understand how ketamine brings about dissociative symptoms.
What is the current status of trial NCT04861051?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2021-07-26. Estimated completion is 2028-08-01.
What conditions does trial NCT04861051 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT04861051?
The interventions under investigation include: Ketamine (DRUG).
Who is sponsoring clinical trial NCT04861051?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04861051 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy
RECRUITING · Phase 1
-
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
RECRUITING · Phase 1
-
Microelectrode Recordings From the Vagus Nerve in Awake Humans
RECRUITING · Phase 1
-
Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy
RECRUITING · Phase 1
-
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.